Home › Aradigm Co. (ARDM) Downgraded to "Sell" at Zacks Investment Research
 

Keywords :   


Aradigm Co. (ARDM) Downgraded to "Sell" at Zacks Investment Research

2016-03-24 14:49:09| Biotech - Topix.net

According to Zacks, "Aradigm Corp. is a leading developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. Their hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via the lung.

Tags: research sell investment downgraded

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
27.06Eastern North Pacific Tropical Weather Outlook
27.06Atlantic Tropical Weather Outlook
27.06Texas & Southwestern Cattle Raisers Association concludes 2024 summer meeting
27.06CCA secures funding for wolf compensation in revised budget
27.06Kimberly-Clark Could Close U.K. Plant
27.06MU Extension to host 3 feedlot educational events this summer
27.06Whats your marketing plan for beef-on-dairy calves?
27.06Sunn hemp can boost summer pastures
More »